Pharmaceuticals News and Research

RSS

Cegedim Dendrite and Ping Identity announce new partnership deal

Cegedim Dendrite and Ping Identity today announced a partnership to enable Internet Single Sign-On security for Cegedim Dendrite’s flagship Customer Relationship Management (CRM) suite, Mobile Intelligence.

22 Dec 2009

ADHD Support Twitter page from Shire

Shire plc, the global specialty biopharmaceutical company, announced the launch of its newest online Attention-Deficit/Hyperactivity Disorder (ADHD) resource, the ADHD Support Twitter(TM) page (http://twitter.com/adhdsupport), derived from the Shire award-winning online educational resource, ADHDSupport.com.

22 Dec 2009

Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA

CSL Limited, Australia’s leading biopharmaceutical company, announced the Journal of the American Medical Association (JAMA) has published data from a clinical trial conducted in Australia to study CSL’s pandemic H1N1 2009 ‘swine’ flu vaccine.

22 Dec 2009

WuXi PharmaTech chosen for the Deloitte Technology Fast 500 Asia Pacific 2009 List

WuXi PharmaTech, a leading pharmaceutical, biotechnology, and medical-device research and development outsourcing company, with operations in China and the United States, announced that it had been selected for the Deloitte Technology Fast 500 Asia Pacific 2009 List, the only company in China to receive this award for the past six years. The Deloitte program recognizes technology companies in the Asia Pacific region that have achieved the highest rates of revenue growth during the preceding three years.

22 Dec 2009

Web-based CME courses to educate physicians on drug industry offered by FSMB Foundation

A new web-based Continuing Medical Education (CME) initiative by the Federation of State Medical Boards Foundation is seeking to educate physicians on various aspects of the relationship between the medical community and the pharmaceutical industry.

22 Dec 2009

Cell Therapeutics supports Code on Interactions with Healthcare Professionals

Cell Therapeutics, Inc. announced today its support of the Pharmaceutical Research Manufacturers of America's (PhRMA) "Code on Interactions with Healthcare Professionals, revised July 2008" (PhRMA Code). Adherence to the Code is voluntary for commercial biotechnology and pharmaceutical companies.

22 Dec 2009

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has received the $20 million milestone payment previously announced on December 1, 2009 relating to the approval of ZEGERID OTC™ (omeprazole 20 mg/sodium bicarbonate 1100 mg capsules) under its over-the-counter (OTC) licensing agreement with Schering-Plough HealthCare Products, Inc., the consumer healthcare division of Merck & Co., Inc. Schering-Plough and Merck merged on November 3, 2009.

22 Dec 2009

Paul Capital Healthcare leads investment to provide more than $100 million to UCB S.A.

Paul Capital Healthcare today announced that it has led an investment to provide more than $100 million to UCB S.A. in exchange for certain payments relating to the sales of products marketed by third parties. The underlying third party products (which are non-core to UCB) are leading brands in their therapeutic fields.

22 Dec 2009

Albany College of Pharmacy Project bonds upgraded to 'BBB+'

Fitch Ratings has upgraded its long-term rating to 'BBB+' from 'BBB-' on $14 million of the Albany Industrial Development Agency civic facility revenue bonds (Albany College of Pharmacy Project). The Rating Outlook is Stable.

22 Dec 2009

Research shows morphine dosage can vary greatly in newborns

Dosage recommendations for newborns being cared for in an intensive care unit will in the future most likely be based on more individual characteristics than just body weight.

22 Dec 2009

Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

Urigen Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development of treatments for urological disorders and pain, announced today that the Company and Oceana Therapeutics have agreed to jointly prepare for a meeting with the U.S. Food & Drug Administration regarding the continued development of URG101.

22 Dec 2009

Amylin Pharmaceuticals' modified exendins and exendin agonists patent: USPTO issues Final Office Action

ConjuChem Biotechnologies Inc. announced today that the U.S. Patent & Trademark Office (USPTO) has issued a Right of Appeal Notice (Final Office Action) in the inter partes reexamination of Patent No. 6,924,264. The patent, entitled "Modified Exendins and Exendin Agonists," was issued in August 2005 and is assigned to Amylin Pharmaceuticals, Inc. The Action once again rejected all the subject claims for obviousness and/or lack of novelty. The inter partes reexamination in the USPTO does not involve any of ConjuChem's patents.

22 Dec 2009

Grant of $1 million awarded to develop new treatments for dyskinesia

The Michael J. Fox Foundation for Parkinson's Research has awarded $1 million for a clinical study aiming to make a critical step toward the development of new treatments for dyskinesia, the excessive and uncontrollable movements that are a complication of long-term dopamine replacement therapy in patients with Parkinson's disease.

22 Dec 2009

CombinatoRx and Neuromed Pharmaceuticals complete merger agreement

CombinatoRx, Incorporated and Neuromed Pharmaceuticals Inc. announced today that they have merged. This merger brings together the product assets and financial resources of both organizations, including potential Exalgo™ milestone and royalty revenue, CombinatoRx’s portfolio of product candidates and unique drug discovery capabilities.

21 Dec 2009

Clarient announces acquisition of Applied Genomics

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced that it has acquired privately held, Huntsville, AL-based Applied Genomics, Inc. (AGI) in an all-stock merger valued at up to $17.6 million, if all conditions and milestones set forth in the merger agreement are successfully met.

21 Dec 2009

Oxford Finance to provide Titan Pharmaceuticals a $3M term loan

Titan Pharmaceuticals, Inc. today announced that it has entered into a Loan and Security Agreement with Oxford Finance Corporation ("Oxford") for a $3 million term loan. The loan will bear interest at an approximate rate of 13% per annum and be payable over three years. Under the terms of the agreement, Titan will pay Oxford an initial facility fee of $60,000 and a final payment fee of $180,000.

21 Dec 2009

Senate Democrats win overnight procedural vote; move one step closer to approving health bill by Christmas

The New York Times: "After a long day of acid, partisan debate, Senate Democrats held ranks early Monday in a dead-of-night procedural vote that proved they had locked in the decisive margin needed to pass a far-reaching overhaul of the nation's health care system."

21 Dec 2009

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Idera Pharmaceuticals, Inc. today announced positive interim results from a Phase 1 clinical trial of IMO-2125 in patients with chronic hepatitis C virus infection (HCV). IMO-2125 is an agonist of Toll-like Receptor 9 that Idera designed to treat HCV by inducing endogenous interferon-alpha and other Th1-type cytokines and chemokines.

21 Dec 2009

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

Teva Pharmaceutical Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today that they have entered into a global license and collaboration agreement to develop and commercialize OGX-011, as well as an agreement to purchase shares in OncoGenex. OGX-011 is a Phase III cancer therapy designed to inhibit cancer treatment resistance.

21 Dec 2009

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Isis Pharmaceuticals, Inc. today announced that it will receive a $10 million payment from OncoGenex Pharmaceuticals, Inc. as a result of OncoGenex' license of OGX-011 to Teva Pharmaceutical Industries Ltd. ( TEVA). OGX-011 is a second-generation antisense drug co-discovered by Isis and OncoGenex that has completed a successful Phase 2 program in patients with advanced prostate cancer and advanced non-small cell lung cancer.

21 Dec 2009

Pharmaceuticals News and Research

Cegedim Dendrite and Ping Identity announce new partnership deal

ADHD Support Twitter page from Shire

Study results of CSL’s pandemic H1N1 2009 vaccine published in JAMA

WuXi PharmaTech chosen for the Deloitte Technology Fast 500 Asia Pacific 2009 List

Web-based CME courses to educate physicians on drug industry offered by FSMB Foundation

Cell Therapeutics supports Code on Interactions with Healthcare Professionals

ZEGERID OTC approval triggers $20M milestone payment to Santarus

Paul Capital Healthcare leads investment to provide more than $100 million to UCB S.A.

Albany College of Pharmacy Project bonds upgraded to 'BBB+'

Research shows morphine dosage can vary greatly in newborns

Urigen Pharmaceuticals and Oceana Therapeutics jointly prepare for meeting with FDA on URG101

Amylin Pharmaceuticals' modified exendins and exendin agonists patent: USPTO issues Final Office Action

Grant of $1 million awarded to develop new treatments for dyskinesia

CombinatoRx and Neuromed Pharmaceuticals complete merger agreement

Clarient announces acquisition of Applied Genomics

Oxford Finance to provide Titan Pharmaceuticals a $3M term loan

Senate Democrats win overnight procedural vote; move one step closer to approving health bill by Christmas

Positive interim results from Idera Pharmaceuticals' IMO-2125 Phase 1 clinical trial for HCV

Teva Pharmaceutical Industries, OncoGenex Pharmaceuticals announce collaboration in cancer therapy

OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries

Event guide: World ADC San Diego eBook

Latest eBooks

A practical guide to lipid nanoparticle formulation and resizing

Editorial Focus eBook - Spatial and single-cell omics (1st edition)

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Managing vibration in IVF laboratories

Improving healthcare sustainability through carbon data

A New Approach to Preventing Bladder Cancer Recurrence